Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2017—Aushon BioSystems and ABL announced that ABL has adopted the Cira platform for multiplex and ultrasensitive biomarker analysis. ABL will offer this proprietary technology as a new addition to its service offerings in support of pharmaceutical and clinical research clients.
December 2017—Binding Site’s Immunologicals Group offers a comprehensive line of disease state sera in its portfolio of products available to in vitro diagnostic manufacturers and clinical research facilities. The line of products follows all current regulatory and quality standards guidelines and provides materials from a variety of disease state conditions, including ANAs, ANCAs, aPLs, ENAs, infectious and contagious diseases, inflammation markers, and autoantibodies focused on a variety of human organs and tissues.
December 2017—DiaSorin Molecular introduced group C and group G Streptococcus primer pairs and a Pneumocystis jirovecii primer pair for the amplification and detection of the Pneumocystis jirovecii mtLSU gene with a CFR610- and BHQ-2-labeled probe and forward and reverse primers.
December 2017—Promega Corp.’s bioluminescent HiBiT Protein Tagging System can be combined with CRISPR/Cas9-mediated gene editing to tag endogenous proteins and simplify their study under natural expression conditions, as demonstrated in a study published in ACS Chemical Biology (Schwinn MK, et al. Epub ahead of print Sept. 21, 2017. doi:10.1021/acschembio.7b00549).
December 2017—Abacus Diagnostica received the CE mark for the GenomEra Norovirus, a molecular in vitro diagnostic test for the detection and differentiation of norovirus genogroups I and II. The test runs on the GenomEra CDX platform.
December 2017—LabCorp and Cancer Genetics have signed agreements with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. Each laboratory will participate in oncology-focused clinical trials in collaboration with pharmaceutical companies and Thermo Fisher.
December 2017—ArcherDx has earned ISO 13485:2003 and EN ISO 13485:2012 certification from the British Standards Institution. This ISO certification indicates that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic assays.
December 2017—Quidel received 510(k) clearance from the FDA to market its Sofia Lyme FIA for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens from patients suspected of B. burgdorferi infection. The test is intended for use with the Sofia analyzer to aid in the diagnosis of Lyme disease.
December 2017—Hologic has received FDA 510(k) clearance for its Panther Fusion Paraflu assay, a multiplexed assay that runs on the Panther Fusion system.
December 2017—Natera announced a second research collaboration with Denmark’s Aarhus University utilizing the company’s research use only technology to evaluate ctDNA as a useful biomarker for detecting minimal residual disease, treatment response, and disease recurrence in colorectal cancer patients. (The university will also use the Signatera technology in a bladder cancer study.)
